XORTX Therapeutics (XRTX) Q2 2025 earnings summary

Executive summary

• Focused on late-stage clinical development of therapies for gout, ADPKD, T2DN, and AKI associated with respiratory virus infection, leveraging proprietary oxypurinol formulations and a pipeline-in-a-product strategy.

• Lead program XRx-026 for gout is advancing toward NDA submission, with FDA feedback clarifying next steps; XRx-008 for ADPKD is preparing for pivotal trials.

• Recent financings raised $1.15 million post-period end, supporting ongoing R&D and regulatory activities.

Financial highlights

• Net loss for Q2 2025 was $717,700 ($0.19/share) versus net income of $170,066 ($0.06/share) in Q2 2024; six-month net loss was $1,416,373 ($0.38/share) compared to $2,848,870 ($1.07/share) loss in 2024.

• Cash balance at June 30, 2025 was $1,063,477, down from $2,473,649 at year-end 2024; working capital was $553,065.

• Operating cash outflow for six months was $1,437,249, with $25,210 used in investing and $24,133 provided by financing activities.

• Research and development expenses increased 176% year-over-year for Q2 and 228% for the six months, driven by clinical trial and translational science costs.

Outlook and guidance

• Plans to submit IND and NDA for XRx-026 in 2025, targeting commercialization in late 2026, with estimated costs of $9–18 million.

• XRx-008 pivotal trial (XRX-OXY-201) for ADPKD planned for H1 2025, subject to financing, with estimated cost of $5–30 million.

• Ongoing CMC, commercialization, and European regulatory activities budgeted at $8–26 million through 2027.

• Additional funding will be required to advance all programs; current cash burn is ~$240,000/month.